Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target

3 episodes
0.50 program credits
35m
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    There is a high unmet treatment need for novel oral LDL-c lowering therapies to be used on top of statins. Can CETP inhibition innovate the clinical management of LDL-c? In this series, three experts review the history on CETP inhibition, explain what we have learned from clinical trials with CETP inhibitors and explore recent data of a novel CETP inhibitor.

    This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits. 

  • Program Highlights

    This educational program consists of 3 presentations on CETP inhibition. 

    What do we know now that could have changed the history of CETP Inhibition?: genetics and biology - John Kastelein, MD, PhD - Amsterdam, The Netherlands 

    • Over the years, there have been a lot of misconceptions about the effects of CETP inhibition. John Kastelein shares what we have learned from genetics and biology on CETP inhibition.

     

    CETP inhibition: Lessons from two decades of clinical trials- Stephen Nicholls, MD – Melbourne, Australia 

    • Stephen Nicholls shares what we have learned from prior clinical trials with CETP inhibitors. 

     

    A novel CETP-inhibitor to target CV risk reduction: Where could it fit in future lipid management?- Erin Michos, MD - Baltimore, MD, US 

    • There is a high unmet need for effective oral LDL-c lowering therapies to be used as an adjunct to high-intensity statins. Can a novel CETP inhibitor fill in this treatment gap? 
  • Instructions

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at info@pace-cme.org

  • Learning Objectives

    • Describe the function of CETP in lipid metabolism
    • Review the evolving insights and accumulating evidence with CETP inhibitors in lipid management
    • Provide an overview on the development of CETP inhibitors and the future clinical landscape 
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with hyperlipidemia. 

  • Accreditation and Credit Designation Statements

    This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 35 minutes of effective education time. 

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

  • Provider(s)/Educational Partner(s)

    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education.  We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice. 

  • Commercial Support

    Funding for this educational program was provided by an unrestricted educational grant from NewAmsterdam Pharma. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule6 Nov 2024